All In Biotech

Drug Trial Radar · NCT07309380

Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D

Double-blinded Placebo-controlled Multi-center Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jun 2027

Primary completion

Jun 2028

Study completion Aug 2028

Sponsor

Sponsor type
Industry
First posted
Dec 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study adopts a multicenter, randomized, double-blind, placebo-parallel controlled design to evaluate the efficacy and safety of L47 in the treatment of chronic hepatitis D. A total of 150 subjects are planned to be enrolled. After passing the screening, they will be randomly assigned to the L47 group or the placebo group at a ratio of 2:1, with liver cirrhosis and subjects' regional distribution as stratification factors. The two groups will receive hepratide (2.1 mg/day) or placebo, respectively. Upon completion of the 48-week double-blind treatment phase, all subjects in each group can enter the open-label treatment follow-up phase, where they may voluntarily choose to receive L47 (2.1 mg/day) treatment or undergo follow-up observation only, until week 144. Subjects who discontinue treatment prematurely during the trial may also enter the open-label treatment follow-up phase. An interim analysis will be conducted after the subjects complete 24 weeks of trial treatment, with the comprehensive response rate at week 24 as the primary endpoint. The analysis will be performed by an independent statistical team. And the interim analysis results will be reviewed by the Independent Data Monitoring Committee (IDMC) . All subjects will complete the 48-week double-blind clinical trial. Throughout the entire study period, the safety of subjects will be closely monitored and evaluated, including the monitoring of adverse events (AEs) and other safety indicators.

Conditions

  • Hepatitis D, Chronic

Interventions

  • Hepalatide 2.1mgDrug

    Continuous treatment with hepalatide 2.1mg sc, qd, for 48 weeks

  • Placebo of HepalatideDrug

    Continuous treatment with placebo of hepalatide for 48 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects who achieved responseTime frame: 48 weeks of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • First Hospital of Jilin University

    Changchun, Jilin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.